BTIG raised its price target on The Oncology Institute to $9.00 from $8.00 and reaffirmed its Buy rating after the company refinanced an $86 million convertible note with a $75 million term loan and $11 million cash payment. Analysts forecast a 50% reduced quarterly loss of $0.07 and 30.3% revenue growth to $156.15 million.
Analyst firm BTIG reiterated its Buy rating for The Oncology Institute and increased its price target to $9.00 from $8.00 when shares were trading around $5.77. The upgrade reflects confidence in the company’s strategic positioning and anticipated financial improvements.
The Oncology Institute completed a strategic refinancing by repaying an $86 million convertible note using a new $75 million term loan and $11 million in cash. This move reduces debt service obligations and strengthens the balance sheet for future investments.
Market analysis indicates roughly 40% upside potential for the stock, supported by a recent 5.3% single-day gain, an 8.7% four-week rally, and a 52-week high of $6.11. Positive sentiment reflects belief in the company’s growth trajectory.
Projections show a quarterly loss narrowing to $0.07 per share, a 50% improvement from last year, while revenues are expected to reach $156.15 million, up 30.3% year-over-year. These forecasts underscore accelerating top-line growth and improved profitability metrics.
